Allergan (AGN) Shareholders Approve Acquisition By AbbVie
Zacks Investment Research | Oct 15, 2019 05:04AM ET
Allergan plc (NYSE:AGN) announced that its shareholders have approved its pending acquisition by AbbVie, Inc. (NYSE:ABBV) . Allergan said that approximately 68.6% of shareholders eligible to vote at Allergan’s extraordinary general meeting of shareholders as well as a special court-ordered meeting of shareholders voted in favor of the transaction.
Allergan announced the definitive transaction to be acquired by AbbVie in a cash-and-stock deal in June this year. AbbVie is offering $120.30 in cash and 0.866 of its share (worth $67.94) for each share of Allergan. The total transaction value is nearly $63 billion. The acquisition is expected to close by early 2020, if all necessary approvals are obtained.
Allergan’s share price has risen 26.4% this year so far against the industry ’s decrease of 8.8%.
AbbVie’s offer represented a premium of 45% to Allergan’s closing price on Jun 24, thereby proving to be rewarding for its shareholders. Moreover, with blockbuster eye drug, Restasis expected to face generic competition, fears of new competition to Allergan’s key drug, Botox and some recent pipeline setbacks, the merger with AbbVie could prove to be the best way out for Allergan.
Meanwhile, AbbVie’s rationale behind the Allergan deal is to add a new blockbuster product to its portfolio, Botox, ahead of generic competition for its blockbuster inflammatory medicine, Humira. Generic versions of Humira are already denting revenues in Europe and are expected to be launched in the United States in 2023. AbbVie is heavily dependent on Humira and is looking to diversify its portfolio.
Approved for therapeutic and aesthetic use, Botox is a key top-line driver for Allergan and looks fit to be the next revenue driver for AbbVie after Humira loses exclusivity. Overall, the Allergan acquisition should diversify AbbVie’s revenue base to markets/categories outside AbbVie’s present drug portfolio and accelerate its non-Humira business.
However, after the deal was announced, some investors expressed concerns that AbbVie has overpaid for Botox as new competitive pressure looms large.
In February 2019, Evolus, Inc.’s (NASDAQ:EOLS) Jeuveau injection, indicated to improve the appearance of glabellar or frown lines, was approved by the FDA, which can pose competition to Botox. In the fall of 2019, Revance Therapeutics, Inc. (NASDAQ:RVNC) will file for approval of DaxibotulinumtoxinA for Injection (DAXI), a rival treatment to Botox for the frown lines indication. It has demonstrated longer duration of efficacy compared to Botox in late-stage studies.
Get The News You Want
Allergan currently has a Zacks Rank #3 (Hold). You can see .
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1% and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.